HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

This study is comparing a new drug combination (HR070803 plus oxaliplatin, 5-FU, and leucovorin) against the standard regimen (nab-paclitaxel plus gemcitabine) as a first-line treatment for advanced pancreatic cancer. Researchers hope the new combination will be more effective. **You may be eligible if...** - You are 18 or older with confirmed advanced pancreatic cancer that has not been treated yet - You have at least one measurable tumor on scans - Your general health is adequate (ECOG 0 or 1) - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - Your pancreatic cancer is a rare subtype (neuroendocrine, acinar cell, pancreatoblastoma, or solid pseudopapillary tumor) - Your cancer has spread to the brain - You have significant heart problems (heart failure, unstable angina, recent heart attack, or serious arrhythmia) - You have had a severe infection requiring hospitalization in the past 4 weeks Talk to your doctor to see if this trial is right for you.